PETVIVO HOLDINGS, INC. TO PRESENT AT AEGIS CAPITAL VIRTUAL CONFERENCE ON MAY 2-4, 2023
April 27 2023 - 8:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an
emerging biomedical device company focused on the commercialization
of innovative medical therapeutics for pets announced today
announced it will present a company overview at the Aegis Capital
Virtual Conference to be held on May 2nd – 4th, 2023.
John Lai, Chief Executive Officer of PetVivo
Holdings, Inc., will provide an overview of the Company’s
revenue-generating innovative veterinary medical device, Spryng™
with OsteoCushion™ Technology, and growth strategy. “I look forward
to sharing our exciting story with the Aegis conference attendees,”
commented Mr. Lai. “We are at an exciting moment in the evolution
of our business and extremely well positioned to build on the
momentum of 2022 as we continue to introduce Spryng to
veterinarians throughout the United States and other parts of the
world.”
Spryng is an injectable veterinary medical
device comprised of millions of micronized extracellular matrix
particles, which are derived from natural components, including
collagen and elastin. OsteoCushion Technology provides both
reinforcing natural joint support to augment and/or reinforce
missing and damaged cartilage, as well as delivers natural
scaffolding to help address tissue defects. These attributes offer
a great solution to manage lameness and joint afflictions, such as
osteoarthritis, for companion animals in a simple in-clinic
administration.
Conference Details:
Event: Aegis Capital Virtual Conference
Conference Dates: May 2nd – 4th, 2023
Presentation Date: Wednesday, May 3rd, 2023
Presentation Time: 12:25 PM – 12:55 PM ET
Location: Virtual
To view to presentation, visit:
https://us02web.zoom.us/j/81590540881
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG™
with OsteoCushion™ technology, a veterinarian-administered,
intraarticular injectable medical device for the management of
lameness and other joint related afflictions, including
osteoarthritis, in dogs and horses, is currently available for
commercial sale.
For more information about PetVivo Holdings,
Inc. and our revolutionary product, Spryng with OsteoCushion
Technology, please contact info1@petvivo.com or visit
https://petvivo.com/.
CONTACT:John Lai, CEOPetVivo Holdings, Inc.Email:
info1@petvivo.com(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available to the Company and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2022 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jun 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024